Condition: SARS-CoV Infection · Covid19 · Corona Virus Infection · Sponsor: University of California, San Francisco
There is an unmet need to evaluate the impact of sub-clinical/mild COVID19 disease in the outpatient setting on prevalent and incident renal injury, as this data is currently unavailable. To capture the diversity of race/ethnic risk and COVID19 related municipal shelter-in-place guidance, the investigators will enroll COVID19-negative and COVID19-positive samples balanced by race/ethnicity from 3 different states, California, Michigan, and Illinois. Study endpoints will be assayed from urine samples mailed to the study team at 2, 6, and 12 months after their date of PCR test, with no requirement for these individuals to leave their homes to participate.
This description comes directly from the study's public registry record.
Minnie Sarwal, M.D., Ph.D. · 6503531532 · minnie.sarwal@ucsf.edu
Tara Sigdel, PhD · 4155023561 · tara.sigdel@ucsf.edu
Always discuss trial participation with your own doctor first.
| UCSF | San Francisco, California, United States | Recruiting |
| Rush University | Chicago, Illinois, United States | Recruiting |
| University of Michigan | Ann Arbor, Michigan, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04705766